PrEP and PEP are important HIV prevention tools that hospitalists should understand and discuss with patients during hospital ...

LOS ANGELES, May 7 (Reuters) - Gilead Sciences (GILD.O), opens new tab posted a higher-than-expected first-quarter profit on Thursday and raised its outlook for 2026 sales, but projected an annual ...

3 Blue-Chip Stocks Built for a Rotating Market Gilead Sciences (NASDAQ:GILD) Chief Commercial Officer and Head of Corporate Affairs Johanna Mercier said the company is leaning on its HIV business ...

Gilead Sciences, Inc. GILD announced that the FDA has granted accelerated approval to Hepcludex (bulevirtide-gmod) for adults with chronic hepatitis delta virus (HDV) infection. The approval makes ...

3 Blue-Chip Stocks Built for a Rotating Market Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, ...

After failing for the second year in a row to pass a budget on time, the Florida Legislature has cobbled together this year’s ...

You’ve probably heard of Ozempic or Wegovy. These are the injectable drugs that have become household names for weight loss ...

GLP-1 drugs aren’t just reducing weight — they may also be reducing the chances of developing one of the most common and ...

Drugs such as semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro) are transforming obesity treatment, but without ...

Gilead stock fell Friday as investors digested a first-quarter report driven by Descovy in HIV prevention, rather than twice-a-year shot Yeztugo. Expectations for Yeztugo have been massive. The ...

Drugs such as semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro) are transforming obesity treatment, but without ...